Publications

2008 - 2015

  1. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto D, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol 2010;46(12):880-887. PMCID:PMC2991505.
  2. *Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg 2011;137(5):499-507. PMCID:PMC3298372.
  3. Adams A, Warner K, Nör JE. Salivary gland cancer stem cells. Oral Oncol. 2013 Sep;49(9):845-53. doi: 10.1016/j. oraloncology.2013.05.013. Epub 2013 Jun 28.Review. PMCID:PMC3744607.
  4. *Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT et al. (2010). Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck 32(2):221-228. PMCID:PMC2967367.
  5. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, Nyati MK. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 2010;70(7):2862-9. PMCID:PMC2848889.
  6. Ahsan A, Hiniker SM, Davis MA, Lawrence TS, Nyati MK. Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res 2009;69(12):5108-14. PMCID:PMC2697971.
  7. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK. Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors. Neoplasia. 2012;14(8):670-7. PMCID:PMC3431175.
  8. Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, Nyati MK. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem. 2013 Sep 13;288(37):26879-86. doi: 10.1074/jbc.M113.492280. Epub 2013 Jul 29. PMCID:PMC3772236.
  9. Ahsan A, Ramanand SG, Bergin IL, Zhao L, Whitehead CE, Rehemtulla A, Ray D, Pratt WB, Lawrence TS, Nyati MK. Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts. Neoplasia. 2014;16:105-114. (Cover Article). PMCID:PMC3978391.
  10. *Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, Kapila YL. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011;117(8):1670-1678. PMCID:PMC3117020.
  11. *Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011;1816(1):80-8. PMCID:PMC3129516.
  12. *Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett. 2009;278(2):201-209. PMCID:PMC3350786.
  13. Almeida LO, Abrahao AC, Rosselli-Murai LK, , Giudice FS, Zagni C, Leopoldino AM, Squarize CH, Castilho RM. NF?B mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio. 2013 Dec 30;4:96-104. doi: 10.1016/j.fob.2013.12.003. eCollection 2014. PMCID:PMC3907686.
  14. *Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clinical Cancer Res 2011;17(17):5755-64. PMCID:PMC3368806.
  15. *Arthur AE, Duffy SA, Sanchez GI, Gruber SB, Terrell JE, Hebert JR, Light E, Bradford CR, D'Silva NJ, Carey TE, Wolf GT, Peterson KE, Rozek LS: "Higher micronutrient intake is associated with human papillomavirus-positive head and neck cancer: a case-only analysis." Nutr Cancer, 63(5):734-42, 2011. PMCID:PMC3391594.
  16. *Arthur AE, Peterson KE, Rozek LS, Taylor JM, Light E, Chepeha DB, Hébert JR, Terrell JE, Wolf GT, Duffy SA; The UM Head Neck SPORE Program. Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis. Am J Clin Nutr. 2013;97(2):360-8. PMCID:PMC3545683.
  17. * Arthur AE, Peterson KE, Shen J, Djuric Z, Taylor JM, Hebert JR, Duffy SA,Peterson LA, Bellile EL, Whitfield JR, Chepeha DB, Schipper MJ, Wolf GT, RozekLS. Diet and proinflammatory cytokine levels in head and neck squamous cell carcinoma. Cancer. 2014 May 15. doi: 10.1002/cncr.28778. [Epub ahead of print]. PMCID:PMC4141000.
  18. *Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S, Nör JE. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther. 2009;8(4):893-903. PMCID:PMC2709836.
  19. *Athanassiou-Papaefthymiou M, Shkeir O, Kim D, Divi V, Matossian M, Owen JH, Czerwinski MJ, Papagerakis P, McHugh J, Bradford CR, Carey TE, Wolf GT, Prince ME, Papagerakis S. Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):337-49. PMCID:PMC4266392.
  20. *Attar E, Dey S, Hablas A, Seifeldin IA, Ramadan M, Rozek LS, Soliman AS. Head and neck cancer in a developing country: a population-based perspective across 8 years. Oral Oncol. 2010;46(8):591-6. PMCID:PMC3223856.
  21. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011;30(1):117-26. PMCID:PMC3000878.
  22. Bandhlish A, Leon Barnes E, Rabban JT, McHugh JB (2011). Perivascular epithelioid cell tumors (PEComas) of the head and neck: report of three cases and review of the literature. Head Neck Pathol 5(3):233-240. PMCID:PMC3173543.
  23. *Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014 Jul 31;5:4527. doi: 10.1038/ncomms5527. PMCID:PMC4130352.
  24. Banerjee R, Van Tubergen EA, Scanlon CS, Vander Broek R, Lints JP, Liu M, Russo N, Inglehart RC, Wang Y, Polverini PJ, Kirkwood KL, D'Silva NJ. The G-protein coupled receptor GALR2 promotes angiogenesis in head and neck cancer. Mol Cancer Ther. 2014 May;13(5):1323-33. doi: 10.1158/1535-7163.MCT-13-0904. Epub 2014 Feb 25. PMCID:PMC4023835.
  25. Banerjee R, Henson BS, Russo N, Tsodikov A, D'Silva NJ. Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma. Cell Signal. 2011;23(7):1110-8. PMCID: PMC3090707.
  26. *Banerjee R, Mani R, Russo N, Scanlon CS, Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart RC, Tomlins S, Bradford C, Carey T, Wolf G, Kalyana-Sundaram S, Chinnaiyan A, Varambally S and D'Silva NJ. The tumor suppressor gene rap1GAP is silenced by mir-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene. 2011;30(42):4339-49. PMCID: PMC3154567.
  27. Banerjee R, Russo N, Liu M, Van Tubergen E, D'Silva NJ. Rap1 and its Regulatory Proteins: The tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer. Small GTPases. 2012 Jul-Sep;3(3):192-7. PMCID:PMC3442808.
  28. Banerjee R, Van Tubergen EA, Scanlon CS, Vander Broek R, Lints JP, Liu M, Russo N, Inglehart R, Wang Y, Polverini PJ, Kirkwood KL, D'Silva NJ. The G-protein Coupled Receptor GALR2 Promotes Angiogenesis in Head and Neck Cancer. Mol Cancer Ther. 2014 Feb 25. [Epub ahead of print] NIHMS571142. PMCID:PMC4023835.
  29. *Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014 Jul 31;5:4527. doi: 10.1038/ncomms5527. PMCID:PMC4130352.
  30. 30. Banerjee R, Van Tubergen EA, Scanlon CS, Vander Broek R, Lints JP, Liu M, Russo N, Inglehart RC, Wang Y, Polverini PJ, Kirkwood KL, D'Silva NJ. The G-protein coupled receptor GALR2 promotes angiogenesis in head and neck cancer. Mol Cancer Ther. 2014 May;13(5):1323-33. doi: 10.1158/1535-7163.MCT-13-0904. Epub 2014 Feb 25. PMCID:PMC4023835.
  31. Bao L, Gorin MA, Zhang M, Ventura AC, Pomerantz WC, Merajver SD, Teknos TN, Mapp AK, Pan Q. Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer. Cancer Res. 2009 Jul 15;69(14):5829-34. Epub 2009 Jun 30. PMCID:PMC2757013.
  32. *Bastola P, Stratton Y, Kellner E, Mikhaylova O, Yi Y, Sartor MA, Medvedovic M, Biesiada J, Meller J, Czyzyk-Krzeska MF. Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy. PLoS One. 2013 Jul 29;8(7):e70030 doi:10.1371/journal.pone .0070030. Print 2013. PMCID:PMC3726479.
  33. Bhojani MS, Nyati MK, Zhao L, Normolle DP, Ross BD, Lawrence TS, Rehemtulla A. Molecular imaging of akt enables early prediction of response to molecular targeted therapy. Transl Oncol. 2011 Jun;4(3):122-5. PMCID:PMC3104693.
  34. Bhojani MS, Ranga R, Luker GD, Rehemtulla A, Ross BD, Van Dort ME. Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS One. 2011;6(7):e22418. PMCID:PMC3139646.
  35. Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, Cordell K, Kleer C, Kupfer R, Kumar P, Urba S, Worden F, Eisbruch A, Wolf GT, Teknos TN, Prince ME, Chepeha DB, Hogikyan ND, Moyer JS, Carey TE. Biomarkers in advanced larynx cancer. Laryngoscope. 2014 Jan;124(1):179-87. doi: 10.1002/lary.24245. Epub 2013 Jul 12. PMCID:PMC4123871.
  36. *Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010;32(4):417-26. PMCID:PMC3292176.
  37. Byrd SA, Spector ME, Carey TE, Bradford CR, McHugh JB. Predictors of recurrence and survival for head and neck mucoepidermoid carcinoma. Otolaryngol Head Neck Surg. 2013 Sep;149(3):402-8. doi: 10.1177/0194599813489659. Epub 2013 May 21. PMCID:PMC4106041.
  38. Bunek J, Kamarajan P, Kapila YL. Anoikis mediators in oral squamous cell carcinoma. Oral Dis. 2011;17(4):355-61. PMCID:PMC3072433.
  39. Butler RT, Spector ME, Thomas D, McDaniel AS, McHugh JB. An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma. Head Neck Pathol. 2014 Jun;8(2):133-40. doi: 10.1007/s12105-013-0493-5. Epub 2013 Sep 25. PMCID:PMC4022941.
  40. Campos MS, Neiva KG, Meyers KA, Krishnamurthy S, Nör JE. Endothelial derived factors inhibit anoikis of head and neck cancer stem cells. Oral Oncol. 2012;48(1):26-32. PMCID:PMC3261237.
  41. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82. PMCID:PMC4311405.
  42. *Cao Y, Popovtzer A, Li D, Chepeha DB, Moyer JS, Prince ME, Worden F, Teknos T, Bradford C, Mukherji SK, Eisbruch A. Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys. 2008;72:1287-1290. PMCID:PMC3638953.
  43. *Chandarana SP, Lee JS, Chanowski EJ, Sacco AG, Bradford CR, Wolf GT, Prince ME, Moyer JS, Eisbruch A, Worden FP, Giordano TJ, Kumar B, Cordell KG, Carey TE, Chepeha DB. Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck. 2013 Aug;35(8):1083-90. doi: 10.1002/hed.23087. Epub 2012 Aug 21. PMCID:PMC4118462.
  44. Chanowski EJ, Casper KA, Eisbruch A, Heth JA, Marentette LJ, Prince ME Prince ME, Moyer JS, Chepeha DB. Restoration of the orbital aesthetic subunit with the thoracodorsal artery system of flaps in patients undergoing radiation therapy. J Neurol Surg B Skull Base. 2013 Oct;74(5):279-85. doi: 10.1055/s-0033-1347366.Epub 2013 Jun 20. PMCID:PMC3774825.
  45. Chinn SB, Darr OA, Peters RD, Prince ME. The role of head and neck squamous cell carcinoma cancer stem cells in tumorigenesis, metastasis, and treatment failure. Front Endocrinol (Lausanne). 2012;3:90. PMCID:PMC3411100.
  46. *Chinn SB, Darr OA, Owen JH, Bellile E, McHugh JB, Spector ME, Papagerakis SM, Chepeha DB, Bradford CR, Carey TE, Prince MEP. Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck. 2014 Jan 10. doi: 10.1002/hed.23600. [Epub ahead of print]. PMCID:PMC4127160.
  47. *Chinn SB, Spector ME, Bellile EL, McHugh JB, Gernon TJ, Bradford CR, Wolf GT, Eisbruch A, Chepeha DB. Impact of perineural invasion in the pathologically N0 neck in oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013 Dec;149(6):893-9. doi: 10.1177/0194599813506867. Epub 2013 Oct PMCID:PMC4118458.
  48. Chinn SB, Spector ME, Bellile EL, Rozek LS, Lin T, Teknos TN, Prince ME, Bradford CR, Urba SG, Carey TE, Eisbruch A, Wolf GT, Worden FP, Chepeha DB. Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma. JAMA Otolaryngol Head Neck Surg. 2014 Feb;140(2):134-42. doi: 10.1001/jamaoto.2013.5892. PMCID:PMC4103099.
  49. *Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-2 Oral Squamous Cell Carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010 Mar 10;28(8):1395-400. PMCID:PMC2834497.
  50. *Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32(9):1195-201. PMCID:PMC2991066.
  51. *Colacino JA, Arthur AE, Dolinoy DC, Sartor MA, Duffy SA, Chepeha DB, Bradford CR, Walline HM, McHugh JB, D'Silva N, Carey TE, Wolf GT, Taylor JM, Peterson KE, Rozek LS. Pretreatment dietary intake is associated with tumor suppressor DNA methylation in head and neck squamous cell carcinomas. Epigenetics. 2012;7(8):883-91. PMCID:PMC3427284.
  52. Colacino JA, Arthur AE, Ferguson KK, Rozek LS. Dietary antioxidant and anti-inflammatory intake modifies the effect of cadmium exposure on markers of systemic inflammation and oxidative stress. Environ Res. 2014 Mar 4;131C:6-12. doi: 10.1016/j.envres.2014.02.003. [Epub ahead of print].PMCID:PMC4057047.
  53. *Colacino JA, Dolinoy DC, Duffy SA, Sartor MA, Chepeha DB, Bradford CR, McHugh JB, Patel DA, Virani S, Walline HM, Bellile E, Terrell JE, Stoerker JA, Taylor JMG, Carey TE, Wolf GT, Rozek LS. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One. 2013;8(1):e54742. PMCID:PMC3554647.
  54. Colacino JA, Arthur AE, Ferguson KK, Rozek LS. Dietary antioxidant and anti-inflammatory intake modifies the effect of cadmium exposure on markers of systemic inflammation and oxidative stress. Environ Res. 2014 Mar 4;131C:6-12. doi: 10.1016/j.envres.2014.02.003. [Epub ahead of print]. PMCID: PMC4057047.
  55. *Czerwinski MJ, Desiderio V, Shkeir O, Papagerakis P, Lapadatescu MC, Owen JH, Athanassiou-Papaefthymiou M, Zheng L, Papaccio G, Prince ME, Papagerakis S. In vitro evaluation of sialyl Lewis X relationship with head and neck cancer stem cells. Otolaryngol Head Neck Surg. 2013 Jul;149(1):97-104. doi:10.1177/0194599813482879. Epub 2013 Apr 4. PMCID:PMC4157351.
  56. *Danciu TE, Chupreta S, Cruz O, Fox JE, Whitman M, Ińiguez-Lluhi JA. Small Ubiquitin-like Modifier (SUMO) modification mediates the function of the inhibitory domains of the developmental regulators FoxC1 and FoxC2. J Biol Chem. 2012;287(22):18318-29. PMCID:PMC3365760.
  57. Danciu TE, Li Y, Koh A, Xiao G, McCauley LK, Franceschi RT. The basic helix loop helix transcription factor Twist1 is a novel regulator of ATF4 in osteoblasts. J Cell Biochem. 2012;113(1):70-9. PMCID: PMC3414260.
  58. *Darr OA, Colacino JA, Tang AL, McHugh JB, Bellile EL, Bradford CR, Prince MP, Chepeha DB, Rozek LS, Moyer JS. Epigenetic alterations in metastatic cutaneous carcinoma. Head Neck. 2014 Apr 2. doi: 10.1002/hed.23701. [Epub ahead of print]. PMCID:PMC4183742.
  59. Davis SJ, Divi V, Owen JH, Bradford CR, Carey TE, Papagerakis S, Prince ME. Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2010;136(12):1260-6. PMCID:PMC3315371.
  60. 60. Demiroz C, Vainshtein JM, Koukourakis GV, Gutfeld O, Prince ME, Bradford CR, Wolf GT, McLean S, Worden FP, Chepeha DB, Schipper MJ, McHugh JB, Eisbruch A. Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy. Head Neck. 2014 Nov;36(11):1589-95. doi:10.1002/hed.23479. PMCID:PMC4241546.
  61. *Desiderio V, Papagerakis P, Tirino V, Zheng L, Matossian M, Prince ME, Paino F, Mele L, Papaccio F, Montella R, Papaccio G, Papagerakis S. Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget. 2015 Jan 1;6(1):71-84. PMCID:PMC4381579.
  62. *Dewyer NA, Wolf GT, Light E, Worden F, Urba S, Eisbruch A, Bradford CR, Chepeha DB, Prince ME, Moyer J, Taylor J. Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer. Head Neck. 2014 Jan;36(1):9-14. doi: 10.1002/hed.23263. Epub 2013 Jun 14. PMCID:PMC4243470.
  63. Divi V, Worden FP, Prince ME, Eisbruch A, Lee JS, Bradford CR, Chepeha DB, Teknos TN, Hogikyan ND, Moyer JS, Tsien CI, Urba SG, Wolf GT. Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck. 2009:32(8):1040-7. PMCID:PMC2891819.
  64. Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos T, Chepeha DB, Walline HM, McHugh JB, Cordell KG, Ward PD, Byrd S, Maxwell JH, Urba S, Bradford CR, Carey TE, Worden FP. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. Head Neck. 2014 May;36(5):617-23. doi:10.1002/hed.23339. PMCID:PMC4205960.
  65. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, Lingen MW, Rosner MR. A novel interplay between Epac/Rap1 and MEK5/ERK5 regulates thrombospondin to control angiogenesis. Blood. 2009;114(20):4592-600. PMCID:PMC2777131.
  66. Donatelli-Lassig AA, Duffy SA, Fowler KE, Ronis DL, Chepeha DB, Terrell JE. The effect of neck dissection on quality of life after chemoradiation. Otolaryngol Head Neck Surg. 2008 Oct;139(4):511-8. PMCID:PMC2840712.
  67. Dong Z, Imai A, Krishnamurthy S, Zhang Z, Zeitlin BD, Nör JE. Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study. PLoS One. 2013 Dec 31;8(12):e84236. doi:10.1371/journal.pone.0084236. eCollection 2013. PMCID:PMC3877272.
  68. Dong Z, Nör JE. Transcriptional targeting of tumor endothelial cells for gene therapy. Adv Drug Deliv Rev. 2009;61(7-8):542-53. PMCID:PMC2727054.
  69. Duffy SA, Karvonen-Gutierrez CA, Ewing LA, Smith PM. Implementation of the Tobacco Tactics program in the Department of Veterans Affairs. J Gen Intern Med. 2010;25 Suppl 1:3-10. PMCID: PMC2806966.
  70. Duffy SA, Khan MJ, Ronis DL, Fowler KE, Gruber SB, Wolf GT, Terrell JE. Health behaviors of head and neck cancer patients the first year after diagnosis. Head Neck. 2008;30(1):93-102. Published before PMCID requirement.
  71. Duffy SA, Ronis DL, McLean S, Fowler KE, Gruber SB, Wolf GT, Terrell JE. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol. 2009;27(12):1969-75. PMCID:PMC2669762.
  72. Duffy SA, Scheumann AL, Fowler KE, Darling-Fisher C, Terrell JE. Perceived difficulty quitting predicts enrollment in a smoking-cessation program for patients with head and neck cancer. Oncol Nurs Forum. 2010 May;37(3):349-56. PMCID:PMC3721671.
  73. Duffy SA, Teknos T, Taylor JM, Fowler KE, Islam M, Wolf GT, McLean S, Ghanem TA, Terrell JE. Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma. Cancer Epidemiology, Biomarkers and Prevention. 2013;22(3):374-81. Epub 2013 Jan 8. PMCID:PMC3596441.
  74. *D'Souza G, Carey TE, William WN Jr, Nguyen ML, Ko EC, Riddell J 4th, , Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL; on behalf of the HNC SPORE HIV supplement consortium. Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients. J Acquir Immune Defic Syndr. 2013 Dec 8. [Epub ahead of print]. PMCID:PMC3999230.
  75. *Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK: Chemo-IMRT of Oropharyngeal Cancer Aiming to Reduce Dysphagia: Swallowing Organs Late Complication Probabilities and Dosimetric Correlates. Int J. Radiation Oncology Biol Phys. 2011;81(3):e93-9. PMCID:PMC3158965.
  76. Eliassen AM, Hauff SJ, Tang AL, Thomas DH, McHugh JB, Walline HM et al. (2012). Head and neck squamous cell carcinoma in pregnant women. Head Neck. 2012 Mar 16. PMCID:PMC3399935.
  77. Farfán F, Ma J, Sartor MA, Michailidis G, Jagadish HV. THINK Back: Knowledge-based Interpretation of High Throughput data. BMC Bioinformatics. 2012 Mar 13;13 Suppl 2:S4. PMCID:PMC3375631.
  78. Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28(16):2732-8. Epub 2010 Apr 26. PMCID:PMC2881852.
  79. *Feng FY, Brenner JC, Hussain M, Chinnaiyan AM. Molecular Pathways: Targeting ETS Gene Fusions in Cancer. Clin Cancer Res. 2014 Jun 23. pii: clincanres.0275.2013. [Epub ahead of print] PMCID:PMC4155001.
  80. Galbán CJ, Mukherji SK, Chenevert TL, Meyer CR, Hamstra DA, Bland PH, Johnson TD, Moffat BA, Rehemtulla A, Eisbruch A, Ross BD. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol. 2009;2(3):184-90. PMCID:PMC2730136.
  81. Genden EM, Ferlito A, Rinaldo A, Silver CE, Fagan JJ, Suarez C, Langendijk JA, Lefebvre JL, Bradley PJ, Leemans CR, Chen AY, Jose J, Wolf GT. Recent changes in the treatment of patients with advanced laryngeal cancer. Head Neck. 2008;30(1):103-10. Published before PMCID requirement.
  82. Gentry SN, Jackson TL. A mathematical model of cancer stem cell driven tumor initiation: implications of niche size and loss of homeostatic regulatory mechanisms. PLoS One. 2013 Aug 19;8(8):e71128. doi: 10.1371/journal.pone.0071128. eCollection 2013. PMCID:PMC3747196.
  83. *Giordano RJ, Cardo-Vila M, Salameh A, Anobom CD, Zeitlin BD, Hawke DH, Valente AP, Almeida FC, Nor JE, Sidman RL, Pasqualini R, Arap W. From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci USA. 2009;107(11):5112-7. PMCID:PMC2841949.
  84. Giudice FS, Pinto DS Jr, Nör JE, Squarize CH, Castilho RM. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One. 2013;8(3):e58672. PMCID:PMC3603970.
  85. Giudice FS, Squarize CH. The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen. 2013 Aug 2;Suppl 5. pii: 003. PMCID:PMC4130654.
  86. Gluck, I., M. Ibrahim, A. Popovtzer, T. N. Teknos, D. B. Chepeha et al., 2008. Skin Cancer of the Head and Neck with Perineural Invasion: Defining the Clinical Target Volumes Based on the Pattern of Failure. Int J Radiat Oncol Biol Phys. 2009;74(1):38-46. PMCID:PMC2702210.
  87. *Gluck I, Feng FY, Lyden T, Haxer M, Worden F, Chepeha DB, Eisbruch A. Evaluating and Reporting Dysphagia in Trials of Chemoirradiation for Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys. 2010;77(3):727-33. PMCID:PMC2878868.
  88. Gomes FG, Nedel F, Alves AM, Nör JE, Tarquinio SB. Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 2013 Feb 7;92(2):101-7. doi:10.1016/j.lfs.2012.10.008. Epub 2012 Nov 21. Review. PMCID:PMC3740377.
  89. Gorin MA, Pan Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Mol Cancer. 2009;8:9. PMCID:PMC2647895.
  90. *Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T, Bradford C, Prince M, Wang CY, Fearon ER, D'Silva NJ. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2010;16(1):65-76. PMCID: PMC2844500.
  91. Gramling S, Rogers C, Liu G, Reisman D. Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene. 2011;30(29):3289-94. PMCID:PMC3402205.
  92. Hadjiiski L, Mukherji S, Gujar S, Sahiner B, Ibrahim M, Moyer J, Chan H. Head and neck cancers on CT: preliminary study of treatment response assessment based on computerized volume analysis. AJR Am J Roentgenol. 2010;194(4):1083-9. PMCID:PMC3729396.
  93. Hadjiiski L, Mukherji SK, Gujar SK, Sahiner B, Ibrahim M, Street E, Moyer J, Worden FP, Chan HP. Treatment response assessment of head and neck cancers on CT using computerized volume analysis. AJNR Am J Neuroradiol. 2010 Oct;31(9):1744-51. PMCID:PMC3767432.
  94. Hamstra, D. A., K. C. Lee, B. A. Moffat, T. L. Chenevert, A. Rehemtulla et al. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol. 2008;1: 187-194. PMCID:PMC2582167.
  95. Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, Yuan CL, Krokowski D, Wang S, Hatzoglou M, Kilberg MS, Sartor MA, Kaufman RJ. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol. 2013 May;15(5):481-90. doi: 10.1038/ncb2738. Epub 2013 Apr 28. PMCID:PMC3692270.
  96. Hegen A, Blois A, Tiron CE, Hellesoy M, Micklem DR, Nor JE, Akslen LA, Lorens JB. Efficient in vivo vascularization of tissue-engineering scaffolds. J Tissue Eng Regen Med. 2011;5(4):e52-62. PMCID: PMC3010488.
  97. Hung J, Hiniker SM, Lucas DR, Griffith KA, McHugh JB, Meirovitz A, Thomas DG, Chugh R, Herman JM. Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases. Sarcoma. 2013;2013:798403. doi: 10.1155/2013/798403. Epub 2013 Sep 3. PMCID:PMC3776386.
  98. Hunter KU, Fernandes LL, Vineberg KA, McShan D, Antonuk AE, Cornwall C, Feng M, Schipper MJ, Balter JM, Eisbruch A. Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):676-82. doi: 10.1016/j.ijrobp.2013.07.040. Epub 2013 Sep 10. PMCID: PMC3805710.
  99. Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head Neck. 2014 Jan;36(1):120-5. doi: 10.1002/hed.23275. Epub 2013 Jun 1. PMCID:PMC4144677.
  100. Hunter K, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch C, Cornwall B, Lee C, Chepeha D, Eisbruch A. Toxicities affecting Quality of Life After Chemo-IMRT of Oropharyngeal Cancer: Prospective Study of Patient-Reported, Observer-Rated, and Objective Outcomes. Int J Radiation Oncology Biology Physics. 2013 Mar 15;85(4):935-40. PMCID:PMC3556374.
  101. *Imai A, Zeitlin BD, Visioli F, Dong Z, Zhang Z, Krishnamurthy S, Light E, Worden F, Wang S, Nör JE. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Cancer Res. 2012;72(3):716-25. PMCID:PMC3748951.
  102. *Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, Kumar P, Teknos TN. RhoC expression and head and neck cancer metastasis. Mol Cancer Res. 2009;7(11):1771-80. PMCID:PMC2887764.
  103. Jain HV, Jackson TL. A hybrid model of the role of VEGF binding in endothelial cell migration and capillary formation. Front Oncol. 2013 May 10;3:102. doi: 10.3389/fonc.2013.00102. eCollection 2013. PMCID:PMC3650479.
  104. *Jain HV, Nör JE, Jackson TL. Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral angiogenesis. Bull Math Biol. 2008;70(1):89-117. Published before PMCID requirement.
  105. *Jain HV, Nör JE, Jackson TL. Quantification of endothelial cell-targeted anti-Bcl-2 therapy and its suppression of tumor growth and vascularization. Mol Cancer Ther. 2009;8(10):2926-36. PMCID: PMC2776748.
  106. 106. *Jo SY, Wang PI, Nör JE, Bellile EL, Zhang Z, Worden FP, Srinivasan A, Mukherji SK. CT perfusion can predict overexpression of CXCL8 (interleukin-8) in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol. 2013 Dec;34(12):2338-42.doi: 10.3174/ajnr.A3610. Epub 2013 Jul 4. PMCID:PMC4270129.
  107. Joo, N. E. Watanabe T, Chen C, Chekenya M, Stallcup WB, Kapila Y. NG2, a novel proapoptotic receptor, opposes integrin alpha4 to mediate anoikis through PKCalpha-dependent suppression of FAK phosphorylation. Cell Death Differ. 2008;15: 899-907. PMCID:PMC3940336.
  108. Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med. 2012;1(3):295-305. PMCID:PMC3544465.
  109. Kamarajan P, Shin JM, Qian X, Matte B, Zhu JY, Kapila YL. ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC. Cancer Med. 2013 Dec;2(6):793-802. doi: 10.1002/cam4.147. Epub 2013 Oct 16. PMCID:PMC3892384.
  110. Kamarajan P, Garcia-Pardo A, D'Silva NJ, Kapila YL. The CS1 segment of fibronectin is involved in human OSCC pathogenesis by mediating OSCC cell spreading, migration, and invasion. BMC Cancer. 2010;10:330. PMCID:PMC3146068.
  111. *Kamarajan P, Alhazzi T, Danciu T, D'Silva NJ, Verdin E, Kapila Y. Receptor interacting protein (RIP) and Sirtuin-3 (SIRT3) are on Opposite Sides of Anoikis Resistance and Tumorigenesis. Cancer. 2012;118(23):5800-10. PMCID:PMC3443499.
  112. *Kanazawa, T., P. K. Kommareddi, T. Iwashita, B. Kumar, K. Misawa et al., 2009. Galanin Receptor Subtype 2 Suppresses Cell Proliferation and Induces Apoptosis in p53 Mutant Head and Neck Cancer Cells. Clin Cancer Res. 2009;15: 2222-2230. PMCID:PMC3315370.
  113. Kaneko T, Okiji T, Kaneko R, Suda H, Nör JE. Gene expression analysis of immunostained endothelial cells isolated from formaldehyde-fixated paraffin embedded tumors using laser capture microdissection--a technical report. Microsc Res Tech. 2009;72(12):908-12. PMCID:PMC2784235.
  114. Kang SY, Deshpande SS, Donneys A, Rodriguez JJ, Nelson NS, Felice PA, Chepeha DB, Buchman SR. Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis. Bone. 2013 Sep;56(1):9-15. doi: 10.1016/j.bone.2013.04.022. Epub 2013 May 1. PMCID: PMC3758112.
  115. Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, Sartor MA, Stringer KA, Jagadish HV, Burant C, Athey B, Omenn GS. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics. 2012;28(3):373-80. PMCID: PMC3268237.
  116. Khan AP, Schinske KA, Nyati S, Bhojani MS, Ross BD, Rehemtulla A. High-throughput molecular imaging for the identification of FADD kinase inhibitors. J Biomol Screen. 2010;15(9):1063-70. PMCID: PMC3108567.
  117. *Khan AP, Contessa JN, Nyati MK, Ross BD, Rehemtulla A. Molecular imaging of epidermal growth factor receptor kinase activity. Analytical Biochemistry. 2011 Oct 1;417(1):57-64. PMCID:PMC3204941.
  118. Kim JH, Sartor MA, Rozek LS, Faulk C, Anderson OS, Jones TR, Nahar MS, Dolinoy DC. Perinatal bisphenol A exposure promotes dose-dependent alterations of the mouse methylome. BMC Genomics. 2014 Jan 17;15:30. doi: 10.1186/1471-2164-15-30. PMCID:PMC3902427.
  119. *Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS, Nör JE. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 2010;70(23):9969-78. PMCID:PMC3058885.
  120. Krishnamurthy S, Nör JE. Head and neck cancer stem cells. J Dent Res. 2012;91(4):334-40. PMCID: PMC3310753.
  121. Krishnamurthy S, Nör JE. Orosphere assay: A method for propagation of head and neck cancer stem cells. Head Neck. 2012 Jul 13. PMCID:PMC3887391.
  122. *Krishnamurthy S, Warner KA, Dong Z, Imai A, Nör C, Ward BB, Helman JI, Taichman RS, Bellile EL, McCauley LK, Polverini PJ, Prince ME, Wicha MS, Nör JE. Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells 32(11):2845-57, 2014. PMCID: PMC4198458.
  123. *Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W. Human TH17 cells are long-lived effector memory cells. Sci Transl Med. 2011;3(104):104ra100. PMCID: PMC3345568.
  124. *Kumar B, Cordell KG, D'Silva N, Prince ME, Adams ME, Fisher SG et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008;134(4):363-369. PMCID:PMC3342859.
  125. *Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26(19):3128-3137. PMCID:PMC2744895.
  126. Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, Teknos TN. Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer. 2010;9:206. PMCID:PMC2922193.
  127. Li Y, VandenBoom TG, 2nd, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69(16):6704-12. PMCID:PMC2727571.
  128. Lin E, Sparano A, Spalding A, Eisbruch A, Worden FP. Sinonasal undifferentiated carcinoma: A 13-year experience at a single institution. Skull Base. 2010;20(2):61-7. PMCID:PMC2853070.
  129. Lin YL, Yuksel Durmaz Y, Nör JE, El-Sayed ME. Synergistic combination of small molecule inhibitor and RNA interference against antiapoptotic Bcl-2 protein in head and neck cancer cells. Mol Pharm 2013;10(7):2730-8. PMCID:PMC4043997.
  130. Lin GC, Akkina S, Chinn S, Prince ME, McHugh JB, Carey T, Zacharek MA. Sinonasal inverted papilloma: prognostic factors with emphasis on resection margins. J Neurol Surg B Skull Base. 2014 Apr;75(2):140-6. doi: 10.1055/s-0033-1363169. Epub 2014 Feb 17. PMCID:PMC3969439.
  131. Lin YL, Jiang G, Zhang Z, Nör JE, El-Sayed MEH. Silencing Bcl-2 Expression in Epithelial Cancer Cells Using "Smart" Particles. J Functional Biomat 5:167-182, 2014. PMCID:PMC4192611.
  132. Little M, Schipper M and Eisbruch A. Reducing Xerostomia After Chemo-IMRT for Head and Neck Cancer: Beyond sparing the Parotid Glands. Int J Radiation Oncology Biology Physics 2012;83(3):1007-1014. PMCID:PMC3288420.
  133. Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M, Chen Z, Xu W, Roberts H, Shepherd FA, Tsao MS, Reisman D . Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene. 2011;30(29):3295-304. PMCID:PMC3400140.
  134. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, oral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25. PMCID:PMC3864356.
  135. Liu M, Scanlon CS, Banerjee R, Russo N, Inglehart RC, Willis AL, Weiss SJ, D'Silva NJ. The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma. Transl Oncol. 2013 Jun 1;6(3):273-81. Print 2013 Jun. PMCID:PMC3660795.
  136. *Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN Jr, Seethala RR, Ferris RL, Gutkind JS. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. Cancer Prev Res (Phila). 2015 Mar;8(3):197-207. doi:10.1158/1940-6207.CAPR-14-0348. Epub 2015 Feb 13. PMCID:PMC4355306.
  137. *Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326(5957):1230. PMCID:PMC2935583.
  138. *Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A et al. HPV-positive/p16 positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010;32(5):562-567. PMCID:PMC2855405.
  139. *Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, Bradford CR, Carey TE. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226-35. PMCID:PMC2822887.
  140. Mayne ST, Gruber SB. Emerging molecular technologies for identifying the risk of second cancers. Cancer Prev Res (Phila). 2009;2(7):605-7. PMCID:PMC2733247.
  141. McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR. p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head and Neck Pathology. 2008;1(2)123-131. PMCID:PMC2807526.
  142. Mehta S, Moon J, Hashmi M, Leblanc M, Huang CH, Rinehart E, Wolf GT, Urba SG, Banerjee SK, Williamson S. Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420. Oncol Rep. 2013 Jun;29(6):2095-100. doi: 10.3892/or.2013.2374. Epub 2013 Apr 2. PMCID:PMC3694610.
  143. Mierzwa M, Nyati MK, Lawrence TS. Recent advances in combined modality therapy. The Oncologists. 2010;15(4):372-81. PMCID:PMC3227964.
  144. Misawa K, Kanazawa T, Misawa Y, Uehara T, Imai A, Takahashi G, Takebayashi S, Cole A, Carey TE, Mineta H. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer. Transl Oncol. 2013 Jun 1;6(3):338-46. Print 2013 Jun. PMCID: PMC3660803.
  145. *Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, Mineta H, Carey TE. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res. 2008;14(23):7604-13. PMCID:PMC3189853.
  146. Miyazawa M, Dong Z, Zhang Z, Neiva KG, Cordeiro MM, Oliveira DT, Nör JE. Effect of PTK/ZK on the angiogenic switch in head and neck tumors. J Dent Res. 2008;87: 1166-1171. PMCID:PMC2654254.
  147. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009;45(4-5):324-334. PMCID: PMC2743485.
  148. Morani AC, Eisbruch A, Carey TE, Hauff SJ, Walline HM, Mukherji SK. Intranodal cystic changes: a potential radiologic signature/biomarker to assess the human papillomavirus status of cases with oropharyngeal malignancies. J Comput Assist Tomogr. 2013 May-Jun;37(3):343-5. doi: 10.1097/RCT.0b013e318282d7c3. PMCID:PMC3658148.
  149. Nahar MS, Kim JH, Sartor MA, Dolinoy DC. Bisphenol A-associated alterations in the expression and epigenetic regulation of genes encoding xenobiotic metabolizing enzymes in human fetal liver. Environ Mol Mutagen. 2014 Apr;55(3):184-95. doi: 10.1002/em.21823. Epub 2013 Nov 9. PMCID:PMC3999958.
  150. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nör JE. Crosstalk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia. 2009;11(6):583-93. PMCID:PMC2685447.
  151. Neiva KG, Warner KA, Campos MS, Zhang Z, Moren L, Danciu TE, Nör JE. Endothelial IL-6 enhances tumor growth and tumor angiogenesis. BMC Cancer 14(1):99, 2014. PMCID:PMC4016552.
  152. Nishimura K, Tsuchiya Y, Okamoto H, Ijichi K, Gosho M, Fukayama M, Yoshikawa K, Ueda H, Bradford C, Carey T, Ogawa T. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma. Br J Cancer. 2014 Jul 17. doi: 10.1038/bjc.2014.395. [Epub ahead of print] PMCID:PMC4134508.
  153. Nör C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman J, Roesler R, Nör JE. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia 16(2): 137-146, 2014. PMCID: PMC3978394.
  154. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012;72(7):1853-1864. PMCID:PMC3320735.
  155. Owen JH, Hauff SJ, Tang AL, Graham MP, Czerwinski MJ, Kaddoura M, Papagerakis S, Bradford CR, Carey TE, Prince ME. UM-SCC-103: A Unique Tongue Cancer Cell Line That Recapitulates the Tumorigenic Stem Cell Population of the Primary Tumor. Ann Otol Rhinol Laryngol. 2014 May 9. [Epub ahead of print]. PMCID:PMC4153472.
  156. *Palanisamy, V; Jakymiw A, Van Tubergen EA, D'Silva NJ, Kirkwood KL. Control of Cytokine mRNA Expression by RNA binding proteins and microRNAs. J Dent Res 2012;91(7):651-8. PMCID: PMC3383846.
  157. Pannone G, Rodolico V, Santoro A, Lo Muzio L, Franco R, Botti G, Aquino G, Pedicillo MC, Cagiano S, Campisi G, Rubini C, Papagerakis S, De Rosa G, Tornesello ML, Buonaguro FM, Staibano S, Bufo P. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer. 2012;7:4. PMCID:PMC3313884.
  158. *Papagerakis S, Bellile E, Peterson LA, Pliakas M, Balaskas K, Selman S, Hanauer D, Taylor JM, Duffy S, Wolf G. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila). 2014 Dec;7(12):1258-69. doi: 10.1158/1940-6207.CAPR-14-0002. PMCID:PMC4372797.
  159. *Papagerakis S, Pannone G, Zheng L, About I, Taqi N, Nguyen NP, Matossian M,McAlpin B, Santoro A, McHugh J, Prince ME, Papagerakis P. Oral epithelial stem cells-Implications in Nörmal development and cancer metastasis. Exp Cell Res. 2014 Jul 15;325(2):111-129. doi: 10.1016/j.yexcr.2014.04.021. Epub 2014 May 5. Review. PMCID:PMC4157336.
  160. Peterson EA, Stanbery L, Li C, Kocak H, Makarova O, Petty EM. SEPT9_i1 and genomic instability: mechanistic insights and relevance to tumorigenesis. Genes Chromosomes Cancer. 2011;50(11):940-9. PMCID:PMC3172617.
  161. Popovtzer, A., I. Gluck, D. B. Chepeha, T. Teknos, J. Moyer et al. The pattern of failure after re-irradiation of recurrent squamous head and neck cancer: Implications for defining the target. Int J Radiat Oncol Biol Phys. 2009;74(5):1342-7. PMCID:PMC2765822.
  162. Popovtzer A, Normolle D, Worden FP, Prince ME, Chepeha DB, Wolf GT, Bradford CR, Lawrence TS, Eisbruch A. Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. Transl Oncol. 2014 Aug;7(4):479-83. doi: 10.1016/j.tranon.2014.04.016. PMCID:PMC4202797.
  163. Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, Kopelman R. Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 2008;8(12):4593-6. PMCID: PMC2772154.
  164. Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009;2009:346345. PMCID:PMC2723756.
  165. Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia. 2011;13(7):570-8. PMCID:PMC3132843.
  166. *Ray D, Shukla S, Allam US, Helman A, Ramanand SG, Tran L, Bassetti M, Krishnamurthy PM, Rumschlag M, Paulsen M, Sun L, Shanley TP, Ljungman M, Nyati MK, Zhang M, Lawrence TS. Tristetraprolin mediates radiation-induced TNF-? production in lung macrophages. PLoS One. 2013;8(2):e57290. doi: 10.1371/journal.pone.0057290. Epub 2013 Feb 28. PMCID:PMC3585360.
  167. *Rehman AO, Wang CY. CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int J Oral Sci. 2009;1(3):105-18. PMCID:PMC3475585
  168. Ritchie KE, Nör JE. Perivascular stem cell niche in head and neck cancer. Cancer Lett. 2013 Sep 10;338(1):41-6. doi: 10.1016/j.canlet.2012.07.025. Epub 2012 Jul 25. Review. PMCID:PMC3500571
  169. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. March 2008;134(5):536-8. Published before PMCID requirement.
  170. Ronis, D. L., S. A. Duffy, K. E. Fowler, M. J. Khan And J. E. Terrell. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. March 2008;134: 241-248. Published before PMCID requirement.
  171. *Rosselli-Murai LK, Almeida LO, Zagni C, Galindo-Moreno P, Padial-Molina M, Volk SL, Murai MJ, Rios HF, Squarize CH, Castilho RM. Periostin responds to mechanical stress and tension by activating the MTOR signaling pathway. PLoS One. 2013 Dec 13;8(12):e83580. doi: 10.1371/journal.pone.0083580. eCollection 2013. PMCID:PMC3862800.
  172. *Russo N, Wang X, Liu M, Banerjee R, Goto M, Scanlon C, Metwally T, Inglehart RC, Tsodikov A, Duffy S, Van Tubergen E, Bradford C, Carey T, Wolf G, Chinnaiyan AM, D'Silva NJ. A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene. 2013 Oct 17;32(42):5026-37. doi:10.1038/onc.2012.532. Epub 2012 Nov 19. PMCID:PMC4083474.
  173. Santoro A, Pannone G, Papagerakis S, McGuff HS, Cafarelli B, Lepore S, De Maria S, Rubini C, Mattoni M, Staibano S, Mezza E, De Rosa G, Aquino G, Losito S, Loreto C, Crimi S, Bufo P, Lo Muzio L. Beta-catenin and epithelial tumors: a study based on 374 oropharyngeal cancers. Biomed Res Int. 2014;2014:948264. doi: 10.1155/2014/948264. Epub 2014 Jan 8. PMCID:PMC3912883.
  174. *Sartor MA, Dolinoy DC, Jones TR, Colacino JA, Prince ME, Carey TE, Rozek LS. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics. 2011;6(6):777-87. PMCID: PMC3142368.
  175. Scheller EL, Kirkpatrick CM, D'Silva NJ, Krebsbach PH, Edwards PC. Bisphosphonates inhibit expression of P63 by oral keratinocytes. J Dent Res. 2011;90(7):894-9. PMCID:PMC3318057.
  176. *Shangary, S., K. Ding, S. Qiu, Z. Nikolovska-Coleska, J. A. Bauer et al., 2008. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther. 2008;7:1533-1542. PMCID:PMC2494594.
  177. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res.
  178. *Tang AL, Hauff, SJ, Owen JH, Graham MP, Czerwinski MJ, Park JJ, Walline H, Papagerakis, S., Stoerker J, McHugh JB, Chepeha D, Bradford CR, Carey TE, Prince ME. UM-SCC-104: a new human papillomavirus-16 positive cancer stem cell containing head and neck squamous cell carcinoma cell line. Head Neck 2012;34(10):1480-91. PMCID:PMC3369005.
  179. *Tang AL, Owen JH, Hauff SJ, Park JJ, Papagerakis S, Bradford CR, Carey TE, Prince ME. Head and neck cancer stem cells: the effect of HPV--an in vitro and mouse study. Otolaryngol Head Neck Surg. 2013 Aug;149(2):252-60. doi: 10.1177/0194599813486599. Epub 2013 Apr 12. PMCID:PMC4086879.
  180. Tarquinio SB, Zhang Z, Neiva KG, Polverini PJ, Nör JE. Endothelial cell Bcl-2 and lymph node metastasis in patients with oral squamous cell carcinoma. J Oral Pathol Med 2012;41(2):124-130. PMCID:PMC3246528.
  181. *Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008;14(19):5977-5983. PMCID:PMC3896456.
  182. *Tsien CI, Nyati MK, Ahsan A, Ramanand SG, Chepeha DB, Worden FP, Helman JI, D'Silva N, Bradford CR, Wolf GT, Lawrence TS, Eisbruch A. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head Neck. 2013 Sep;35(9):1323-30. doi: 10.1002/hed.23128. Epub2012 Aug 21. PMCID:PMC4364542.
  183. Van Dort ME, Rehemtulla A, Ross BD. PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. Curr Comput Aided Drug Des. 2008;4(1):46-53. PMCID:PMC2756754.
  184. Vainshtein J, McHugh JB, Spector ME, Walline HM, Komarck CM, Stenmark MH, Prince ME, Worden FP, Wolf GT, Bradford CR, Chepeha DB, Carey T, Eisbruch A. Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. Head Neck. 2015 Jan;37(1):8-11. doi:10.1002/hed.23548.PMCID:PMC4153786.
  185. *Vainshtein JM, Spector ME, McHugh JB, Wong KK, Walline HM, Byrd SA, Komarck CM, Ibrahim M, Stenmark MH, Prince ME, Bradford CR, Wolf GT, McLean S, Worden FP, Chepeha DB, Carey T, Eisbruch A. Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014 Feb 22. pii: S1368-8375(14)00037-2. doi: 10.1016/j.oraloncology.2014.02.001. PMCID:PMC4086868.
  186. Vainshtein JM, Spector ME, Stenmark MH, Bradford CR, Wolf GT, Worden FP, Chepeha DB, McHugh JB, Carey T, Wong KK, Eisbruch A. Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014 Mar;50(3):234-9. doi: 10.1016/j.oraloncology.2013.12.003. Epub 2013 Dec 31. PMCID:PMC4159357.
  187. *Van Tubergen EA, Banerjee R, Liu M, Vander Broek R, Light E, Kuo S, Feinberg SE, Willis AL, Wolf G, Carey T, Bradford C, Prince M, Worden FP, Kirkwood KL, D'Silva NJ. Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6. Clin Cancer Res. 2013;19(5):1169-79. PMCID:PMC3594656.
  188. *Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, Bradford C et al. Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer: 2011;117(12)2677-89. PMCID:PMC3574798.
  189. Visioli F, Wang Y, Alam GN, Ning Y, Rados PV, Nör JE, Polverini PJ. Glucose-regulated protein 78 (Grp78) confers chemoresistance to tumor endothelial cells under acidic stress. PLoS One. 2014 Jun 25;9(6):e101053. doi: 10.1371/journal.pone.0101053. eCollection 2014. PubMed PMID: 24964091; PubMed Central PMCID:PMC4071032.
  190. *Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, Graham MP, Bellile E, Moyer JS, Prince ME, Wolf GT, Chepeha DB, Worden FP, Stenmark MH, Eisbruch A, Bradford CR, Carey TE. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Head Neck Surg. 2013 Dec;139(12):1320-7. doi:10.1001/jamaoto.2013.5460. PMCID:PMC4049419.
  191. Wang J, Chen J, Zhang K, Zhao Y, Nör JE, Wu J. TGF-?1 regulates the invasive and metastatic potential of mucoepidermoid carcinoma cells. J Oral Pathol Med. 2011;40(10):762-8. PMCID: PMC3723136.
  192. Wang X, Zhang Z, Chang S, Czajka-Jakubowska A, Nör JE, Clarkson BH Ni L, Liu J. Fluorapatite enhances mineralization of mesenchymal/endothelial cocultures. Tissue Eng Part A. 2014 Jan;20(1-2):12-22. doi: 10.1089/ten.TEA.2013.0113. Epub 2013 Sep 21. PMCID:PMC3875212.
  193. Wang Y, Alam GN, Ning Y, Visioli F, Dong Z, Nör JE, Polverini PJ. The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway. Cancer Res. 2012;72(20):5396-406. PMCID:PMC3743425.
  194. Wang Y, Ning Y, Alam GN, Jankowski BM, Dong Z, Nör JE, Polverini PJ. Amino acid deprivation promotes tumor angiogenesis through the GCN2/ATF4 pathway. Neoplasia. 2013 Aug;15(8):989-97. PMCID:PMC3730049.
  195. Wansom D, Light E, Thomas D, Worden F, Prince M, Urba S, Chepeha D, Kumar B, Cordell K, Eisbruch A Taylor J, Moyer J, Bradford C, D'Silva NJ, Carey T, McHugh J, Wolf G. Infiltrating Lymphocytes and Human Papillomavirus-16 Associated Oropharynx Cancer. Laryngoscope. 2012;122(1):121-7. PMCID: PMC3337032.
  196. Wansom D, Light E, Worden F, Prince M, Urba S, Chepeha DB, Cordell K, Eisbruch A, Taylor J, D'Silva N, Moyer J, Bradford CR, Kurnit D, Kumar B, Carey TE, Wolf GT. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2010;136(12):1267-73. PMCID:PMC3342998.
  197. Ward BB, Dunham T, Majoros IJ, Baker JR Jr. Targeted dendrimer chemotherapy in an animal model for head and neck squamous cell carcinoma. J Oral Maxillofac Surg. 2011;69(9):2452-9. PMCID: PMC3162993.
  198. *Warner KA, Adams A, Bernardi L, Nor C, Finkel KA, Zhang Z, McLean SA, Helman J, Wolf GT, Divi V, Queimado L, Kaye FJ, Castilho RM, Nör JE. Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol. 2013 Nov;49(11):1059-66. doi: 10.1016/j.oraloncology.2013.08.004. Epub 2013 Sep 12. PMCID: PMC3821871.
  199. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, Nör JE. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia. 2008;10(2):131-9. PMCID:PMC2244688.
  200. *Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2012;61(6):738-8. PMCID: PMC3721338.
  201. 201. Williamson SK, Moon J, H. HC, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG. A Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420. Journal of Clinical Oncology. 2010;28(20):3330-5. PMCID: PMC2903329.
  202. *Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D, McHugh J; University of Michigan Head and Neck SPORE Program. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2015 Jan;51(1):90-5. doi: 10.1016/j.oraloncology. PMCID:PMC4268429.
  203. Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31. PMCID:PMC4062188.
  204. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JMG, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146, 2008. PMCID:PMC2742158.
  205. Worden FP, Moyer J, Lee JS, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Hogikyan N, Lassig AA, Emerick K, Mukherji S, Hadjiski L, Tsien CI, Miller TH, Wallace NE, Mason HL, Bradford CR, Wolf GT. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope. 2009;119(8):1510-7. PMCID: PMC2739984.
  206. *Wu ZQ, Rowe RG, Lim KC, Lin Y, Willis A, Tang Y, Li XY, Nör JE, Maillard I, Weiss S. A Snail1/Notch1 Signaling Axis Controls Embryonic Vascular Development. Nat Comms 5;3998, 2014. PMCID: PMC4052376.
  207. *Xu Y, Zhou J, Carey TE, McHugh JB, Voorhees JJ, Fisher GJ. Receptor-type Protein Tyrosine Phosphatase ? Regulates Met Phosphorylation and Function in Head and Neck Squamous Cell Carcinoma. Neoplasia. 2012;14(11):1015-22. PMCID:PMC3514745.
  208. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011 Dec;9(12):1658-67. PMCID:PMC3243808.
  209. Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg. 2009;135(9):869-74. PMCID:PMC3098124.
  210. Yu S, Qin D, Shangary S, Chen J, Wang G, Ding K, McEachern D, Qiu S, Nikolovska-Coleska Z, Miller R, Kang S, Yang D, Wang S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2009;52(24):7970-3. PMCID:PMC2795799.
  211. *Zeitlin BD, Dong Z, Nör JE. RAIN-Droplet: a novel 3D in vitro angiogenesis model. Lab Invest. 2012 Jul;92(7):988-98. doi: 10.1038/labinvest.2012.77. Epub 2012 May 7. PubMed Central PMCID:PMC4043634.
  212. Zeitlin B, Ellis LM, Nor J. Inhibition of VEGFR1/Wnt/B-catenin Crosstalk Leads to Tumor Cell Death. Clin Cancer Res. 2009;15:7453-5. PMCID:PMC2796551.
  213. Zeitlin BD, Nör JE. Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. Curr Top Microbiol Immunol. 2011;348:115-37. PMCID:PMC3812667.
  214. Zeitlin BD, Spalding AC, Campos MS, Ashimori N, Dong Z, Wang S, Lawrence TS, Nör JE. Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. Int J Radiat Oncol Biol Phys. 2010;78(3):879-87. PMCID:PMC2946486.
  215. Zeitlin BD, Zeitlin IJ, Nör JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol. 2008;26(25):4180-8. PMCID:PMC2654265.
  216. *Zhang X, Junior CR, Liu M, Li F, D'Silva NJ, Kirkwood KL. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Oral Oncol. 2013 Feb;49(2):119-28. doi: 10.1016/j.oraloncology.2012.08.004. Epub 2012 Sep 16.PMCID:PMC3527639.
  217. *Zhang X, Rossa C, Liu M, Li F, D'Silva NJ, Kirkwood KL. Oral Squamous Carcinoma Cells Secrete RANKL Directly Supporting Osteolytic Bone Loss. 2013;49(2):119-28. PMCID:PMC3527639.
  218. Zhang Y, Lin YH, Johnson TD, Rozek LS, Sartor MA. PePr: a peak-calling prioritization pipeline to identify consistent or differential peaks from replicated ChIP-Seq data. Bioinformatics. 2014 Jun 3. pii: btu372. [Epub ahead of print]. PMCID:PMC4155259.
  219. Zhang Z, Filho MS, Nör JE. The biology of head and neck cancer stem cells. Oral Oncol. 2012 Jan;48(1):1-9. PMCID:PMC3261238.
  220. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010;17(3):499-512. PMCID:PMC2822115.
  221. Zhang Z, Dong Z, Lauxen I, Sant'Anna M, Nör JE. Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res 74(10):2869-2881, 2014. PMCID:PMC4028029.
  222. Zhao L, Feng D, Bellile EL, Taylor JM. Bayesian random threshold estimation in a Cox proportional hazards cure model. Stat Med. 2014 Feb 20;33(4):650-61. doi: 10.1002/sim.5964. Epub 2013 Sep 6.PMCID:PMC4167617.
  223. *Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN. Assembly and initial characterization of a panel of 85 genomically validated cell lines. Clin Cancer Res 2011;17(23):7248-64. PMCID:PMC3229662.
  224. Zhao W, Liu M, D'Silva NJ, Kirkwood KL. Tristetraprolin Regulates IL-6 Expression Through p38 MAPK Dependent Affinity Changes with mRNA 3'UTR. J Interferon Cytokine Res. 2011;31(8):629-37. PMCID: PMC3151618.
  225. Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, Carry JC, Deschamps JR, Sun D, Wang S. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 2013 May 15;135(19):7223-34. doi: 10.1021/ja3125417. Epub 2013 May 3.PMCID:PMC3806051.
  226. *Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem. 2013 Jul 11;56(13):5553-61. doi: 10.1021/jm4005708. Epub 2013 Jun 20. PMCID:PMC3880646.
  227. Zhu Z, Xu X, Yu Y, Graham M, Prince ME, Carey TE, Sun D. Silencing heat shock protein 27 decreases metastatic behavior of human head and neck squamous cell cancer cells in vitro. Mol Pharm. 2010 Aug 2;7(4):1283-90. doi: 10.1021/mp100073s. PMCID:PMC2914182.

* Asterisks denote publications that publications that crossed or were collaborative between programs.

back to top

Bookmark and Share


Contact Us

Director:
Gregory Wolf M.D.
Co-Director:
Jacques E. Nö, D.D.S., Ph.D.
Head and Neck SPORE
U-M Comprehensive Cancer Center NCRC
2800 Plymouth Road
Building 100, Room 110
Ann Arbor, MI 48109-2800
PH: 734-615-6245
FX: 734-615-6246